Market Overview

AbbVie Reports Q3 Earnings Beat

AbbVie Reports Q3 Earnings Beat

AbbVie (NYSE: ABBV) reported third-quarter earnings of $2.33 per share on Friday, which beat the analyst consensus estimate of $2.30 by 1.3%. This is a 8.88% increase over earnings of $2.14 per share from the same period last year.

The company reported quarterly sales of $8.479 billion, which beat the analyst consensus estimate of $8.38 billion by 1.18%. This is a 2.95% increase over sales of $8.236 billion the same period last year.

"Strong performance from our Immunology and Hematologic Oncology portfolios led our growth this quarter,” said Richard Gonzalez, CEO of AbbVie. “We are also making excellent progress with several key strategic priorities, including the recent launch of our two new immunology therapies - Rinvoq and Skyrizi - both of which are off to an impressive start, as well as continued progress toward the completion of our planned acquisition of Allergan. Based on the continued momentum of our portfolio, we are once again raising our full year 2019 EPS guidance range and increasing our dividend."

AbbVie shares closed Thursday's session at $80.49. The stock has a 52-week high of $94.98 and a 52-week low of $62.66.

Posted-In: Earnings News Pre-Market Outlook


Related Articles (ABBV)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at